New non-invasive test to detect bladder cancer could spare patients cystoscopy

February 1, 2017
New non-invasive test to detect bladder cancer could spare patients cystoscopy
Credit: University College London

A new test for bladder cancer could enable GPs to test a urine sample and spare patients the discomfort of a cystoscopy in hospital, according to UCL research published today in Clinical Epigenetics.

The , called UroMark, has been developed by UCL researchers and uses cutting edge genomic sequencing to detect abnormal cancer DNA in a . The research team, led by Professor John Kelly and Dr Andy Feber (UCL Cancer Institute), identified a panel of DNA alterations which are highly specific to and found that when used on DNA from , UroMark detected bladder cancer with a high degree of accuracy (98% of cases), equivalent to a cystoscopy, currently the clinical gold standard.

The study was carried out on 300 and the UK Medical Research Council has awarded £1.42 million for two larger trials which are currently underway across 32 hospitals. The trials will confirm the accuracy of UroMark before it becomes widely available for clinical use.

Approximately 11,000 people are diagnosed with bladder cancer each year in the UK. For most people, an early sign of bladder cancer is blood in their urine (haematuria), but many patients experience symptoms such as recurrent infection; and the urgency and irritation to urinate.

Normally, patients with blood in their urine are sent to hospital for tests, which include passing an instrument along the water pipe or urethra to inspect the bladder (cystoscopy). The will avoid the need for cystoscopy for many patients and can be tested by GPs if cancer is suspected.

Professor John Kelly said: "We have good evidence that patients, particularly females, are diagnosed late with bladder cancer and often patients visit a GP several times with symptoms prior to detection. Having the UroMark test available to GPs will mean that patients can be tested at an early stage to rule out bladder cancer."

The team anticipate that UroMark will reduce the costs of having to refer patients to hospital. In the UK around 110,000 cystoscopies are performed each year, at a cost to the NHS in the region of £55.39 million.

Explore further: What you need to know about bladder cancer

More information: Andrew Feber et al. UroMark—a urinary biomarker assay for the detection of bladder cancer, Clinical Epigenetics (2017). DOI: 10.1186/s13148-016-0303-5

Related Stories

What you need to know about bladder cancer

July 26, 2016
Bladder cancer accounts for 5 percent of all new cancer diagnoses in the U.S. with nearly 77,000 new cases annually; 1,100 people died of bladder cancer in Kentucky between 2010 and 2014.

Invisible blood in urine may indicate bladder cancer

August 31, 2014
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians.

Bladder cancer clinical trial opens to patients

October 13, 2016
A bladder cancer clinical trial led by scientists at the University of Sheffield and funded by Yorkshire Cancer Research is now recruiting patients.

'Scent device' could help detect bladder cancer

July 8, 2013
Researchers from the University of Liverpool and University of the West of England, (UWE Bristol), have built a device that can read odours in urine to help diagnose patients with early signs of bladder cancer.

Urine test could help detect aggressive bladder cancer

November 29, 2013
A simple urine test could distinguish between aggressive and less aggressive bladder cancers according to a new Cancer Research UK study published in the British Journal of Cancer.

Highly reliable urine test developed for the early detection of a common type of bladder cancer

October 21, 2015
A panel of five biomarkers that can detect the presence of transitional cell bladder carcinoma in urine with 100 per cent specificity has been developed by A*STAR researchers. The noninvasive technique could be developed ...

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.